Forte Biosciences, Inc.

NasdaqCM:FBRX Stok Raporu

Piyasa değeri: US$6.1m

Forte Biosciences Temettü

Temettü kriter kontrolleri 0/6

Forte Biosciences does not have a record of paying a dividend.

Anahtar bilgiler

n/a

Temettü verimi

-404.4%

Geri Alım Getirisi

Toplam Hissedar Getirisi-404.4%
Gelecekteki Temettü Verimin/a
Temettü Büyümesin/a
Bir sonraki temettü ödeme tarihin/a
Eski temettü tarihin/a
Hisse başına temettün/a
Ödeme oranın/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

Jul 17
We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Mar 14
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?

Large Forte Biosciences shareholder scolds company board of directors

Aug 24

We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Aug 17
We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely

Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Aug 16

Forte Biosciences large shareholders make demands for company's future

Jul 07

We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

Dec 23
We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully

Forte Biosciences files for $300M mixed shelf offering

May 28

Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

Mar 13
Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?

Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Jan 19
Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis

Dec 18

Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Nov 25
Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?

Forte Biosciences readies equity offering

Oct 28

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: Insufficient data to determine if FBRX's dividends per share have been stable in the past.

Büyüyen Temettü: Insufficient data to determine if FBRX's dividend payments have been increasing.


Piyasaya Karşı Temettü Getirisi

Forte Biosciences Piyasaya Karşı Temettü Getirisi
FBRX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
SegmentTemettü Verimi
Şirket (FBRX)n/a
Pazarın Alt %25'i (US)1.5%
Pazarın En İyi %25'i (US)4.5%
Sektör Ortalaması (Biotechs)2.2%
Analist tahmini (FBRX) (3 yıla kadar)n/a

Önemli Temettü: Unable to evaluate FBRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Yüksek Temettü: Unable to evaluate FBRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Insufficient data to calculate FBRX's payout ratio to determine if its dividend payments are covered by earnings.


Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as FBRX has not reported any payouts.


Güçlü temettü ödeyen şirketleri keşfedin